Resonant Capital Advisors LLC Buys 426 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Resonant Capital Advisors LLC increased its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,036 shares of the medical equipment provider’s stock after acquiring an additional 426 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Zimmer Biomet were worth $492,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Clear Street Markets LLC bought a new stake in Zimmer Biomet during the fourth quarter worth $27,000. Dark Forest Capital Management LP bought a new stake in Zimmer Biomet during the first quarter worth $35,000. Lazard Asset Management LLC lifted its holdings in Zimmer Biomet by 70.5% during the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 117 shares during the period. Activest Wealth Management lifted its holdings in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 275 shares during the period. Finally, KB Financial Partners LLC bought a new stake in Zimmer Biomet during the first quarter worth $49,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $119.43 on Friday. The stock has a market cap of $24.54 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 2.19 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25. The stock has a fifty day moving average of $126.33 and a 200-day moving average of $119.16. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.15 by $0.05. The company had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $1.88 earnings per share. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is 19.63%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.95% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. Truist Financial lifted their price target on Zimmer Biomet from $133.00 to $135.00 and gave the stock a “hold” rating in a report on Friday, February 9th. Evercore ISI raised their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. raised their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. Finally, Canaccord Genuity Group reissued a “hold” rating and issued a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.